WO2010085648A2 - Procédé de réduction des lésions tissulaires induites par une irradiation - Google Patents

Procédé de réduction des lésions tissulaires induites par une irradiation Download PDF

Info

Publication number
WO2010085648A2
WO2010085648A2 PCT/US2010/021809 US2010021809W WO2010085648A2 WO 2010085648 A2 WO2010085648 A2 WO 2010085648A2 US 2010021809 W US2010021809 W US 2010021809W WO 2010085648 A2 WO2010085648 A2 WO 2010085648A2
Authority
WO
WIPO (PCT)
Prior art keywords
tweak
antibody
radiation therapy
pharmaceutical composition
radiation
Prior art date
Application number
PCT/US2010/021809
Other languages
English (en)
Other versions
WO2010085648A3 (fr
Inventor
Burkly C. Linda
Taeko Dohi
Original Assignee
Linda Burkly C
Taeko Dohi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Linda Burkly C, Taeko Dohi filed Critical Linda Burkly C
Publication of WO2010085648A2 publication Critical patent/WO2010085648A2/fr
Publication of WO2010085648A3 publication Critical patent/WO2010085648A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • This invention involves methods for preventing or reducing the severity of tissue damage resulting from radiation therapy.
  • Radiation therapy also known as radiotherapy, X-ray therapy, and irradiation
  • Radiation therapy is the medical use of ionizing radiation in cancer treatment to kill malignant cells and shrink tumors. About 50 to 60 percent of cancer patients receive some type of radiation therapy during the course of their treatment. Radiation therapy is painless, but has several acute side effects, including damage to epithelial surfaces in the area of the body under treatment. In these tissues, both single-cell damage (necrosis or apoptosis) and interstitial damage (edema, fibrosis, vascular alterations, cellular infiltrations) resulting in tissue remodeling can occur. Epithelial surfaces such as oral, pharyngeal, and bowel mucosa, skin, and urothelium are particularly prone to damage.
  • Radiation therapy injures or destroys cells by damaging their DNA, making it impossible for these cells to continue to grow and divide.
  • the damage is caused by a photon, electron, proton, neutron, or ion beam directly or indirectly ionizing the atoms which make up the DNA chain.
  • the radiation is administered either from a machine outside of the body (as in external beam radiotherapy, or teletherapy), or it may be placed inside the body (brachytherapy, or sealed source radiotherapy) or may be emitted from unsealed radioactive materials that go throughout the body (systemic radioisotope therapy, or unsealed source radiotherapy).
  • radiation may be used alone or in combination with other cancer treatments, such as chemotherapy or surgery, and a patient can receive more than one type of radiation therapy.
  • Radiation can be used as palliative treatment, where cure is not possible and the aim is for local disease control or symptomatic relief, or it can be used as therapeutic treatment, where the therapy has survival benefit and it can be curative. It can also be used as prophylactic treatment, with the intent of preventing cancer formation in a specific area that receives the radiation.
  • Radiation therapy may be used to treat almost every type of solid tumor, including cancers of the lung, brain, breast, cervix, prostate larynx, pancreas, skin, stomach, or uterus, and soft tissue sarcomas. Radiation may also be used to treat leukemia and lymphoma.
  • the dosage of radiation depends on a number of factors, including the radiosensitivity of each cancer type and whether there are tissues and organs nearby that may be damaged by radiation. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly.
  • the goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue. Hence, it is typically given in many fractions, allowing healthy tissue to recover between fractions.
  • Radiation therapy can be external beam radiotherapy (EBRT or XBRT, also known as teletherapy), brachytherapy (also known as sealed source radiotherapy or endocurietherapy), and systemic radioisotope therapy (also known as unsealed source radiotherapy).
  • EBRT or XBRT external beam radiotherapy
  • brachytherapy also known as sealed source radiotherapy or endocurietherapy
  • systemic radioisotope therapy also known as unsealed source radiotherapy.
  • the differences between types of radiation therapy relate to the position of the radiation source: external is outside the body, brachytherapy uses sealed radioactive sources placed precisely in the area under treatment, and systemic radioisotope therapy uses radioisotopes administered by infusion or oral ingestion.
  • Brachytherapy can use temporary or permanent placement of radioactive sources.
  • Proton therapy is a special case of external beam radiotherapy where the particles are protons.
  • Introperative radiotherapy is a special type of radiotherapy that is delivered immediately after surgical removal of the cancer. This method has been employed
  • Epithelial surfaces such as oral, pharyngeal, and bowel mucosa, skin, and urothelium are particularly prone to damage. If the head and neck area is treated, damage to the lining of the mouth and throat that can create temporary soreness, mucositis (an inflammation of the mucous membranes in the mouth), infection, bleeding, pain, and ulceration. If severe, this can affect swallowing, and the patient may need painkillers and nutritional support. While most of these complications are manageable, they can sometimes become severe enough that treatment must be completely stopped or the dose limited, which may also reduce the therapeutic effect of the radiation against the cancer cell targets.
  • the lining of the esophagus can easily be damaged and become sore if the esophagus receives a dose of collateral radiation during treatment of lung cancer or if it is treated directly.
  • the lower bowel is treated with radiation, as in cases of rectal or anal cancer, or is exposed by radiotherapy to other pelvic structures (bladder, male prostate, female genital tract), epithelial damage frequently produces localized inflammation, nausea, vomiting, cramping abdominal pain, and diarrhea.
  • skin is easily damaged by radiation therapy. In areas receiving radiation, skin typically starts to become pink and sore several weeks into treatment.
  • the reaction may become more severe during the treatment and for up to about one week following the end of radiotherapy, and the skin may break down in a process called moist desquamation, characterized by sloughing of the epidermis and exposure of the dermal layer.
  • moist desquamation characterized by sloughing of the epidermis and exposure of the dermal layer.
  • the rates of onset of damage and recovery from it depend upon the turnover rate of the epithelial cells.
  • Intestinal epithelia have rapid cell turnover rates, accompanied by an equally high rate of apoptosisfor maintaining mucosal homeostasis.
  • Intestinal epithelial cells especially rapidly proliferating cells in the crypts (i.e. mucosal glands), are highly sensitive to both cancer chemotherapy and ⁇ -irradiation. DNA damage caused by exposure to cytotoxic agents or ⁇ -irradiation initiates either a self-repairing process or apoptosis to eliminate injured cells. In the latter situation, cytotoxic treatment results in excessive epithelial apoptosis or dysregulation of apoptosis.
  • the methods of the invention relate, in part, to a discovery that disruption of the activity of TNF (Tumor necrosis factor) family member TWEAK (TNF-like weak inducer of apoptosis) reduces the levels of epithelial cell death and results in increased epithelial cell regeneration in mice following tissue injury by ⁇ -irradiation. Accordingly, the invention provides methods of preventing radiation-induced cell death in a subject using a therapeutically effective amount of a TWEAK antagonist. These methods are useful for treating, preventing, and/or reducing the severity of epithelial cell and tissue damage in subjects receiving radiation therapy for the treatment of cancer and other conditions and in subjects who are otherwise exposed to radiation.
  • TNF Tumor necrosis factor
  • TWEAK TNF-like weak inducer of apoptosis
  • Embodiments of the invention encompass the use of an antagonist of TWEAK for preventing or reducing cell death that occurs as a result of radiation therapy or radiation exposure.
  • the methods comprise administering to a subject who has received, is receiving, or will receive radiation therapy a therapeutically effective amount of a TWEAK antagonist sufficient to prevent or reduce the severity of radiation-induced cell death.
  • the subject has cancer.
  • the cancer is a solid cancer.
  • the cancer is a hematologic cancer.
  • the radiation therapy is palliative radiation therapy, wherein cure is not possible, but radiation therapy can, for example, aid in local disease control or symptomatic relief.
  • the radiation therapy is prophylactic radiation therapy.
  • the radiation therapy is locally administered to a specific area of tissue.
  • the therapy is total body irradiation.
  • the subject receives total body irradiation prior to receiving a bone marrow transplant.
  • the methods of the invention prevent or reduce the severity of radiation-induced cell death of epithelial cells.
  • the epithelial cells are gastrointestinal epithelial cells.
  • the gastrointestinal epithelial cells are cells of the jejunum, ileum, or colon.
  • the TWEAK antagonist is an anti-TWEAK antibody or an anti-TWEAK receptor antibody.
  • the antibody is a full length IgG.
  • the antibody is an antigen- binding fragment of a full length IgG.
  • the antibody can be a monoclonal or humanized antibody.
  • the antibody can contain a human Fc region.
  • the TWEAK antagonist is a soluble TWEAK receptor (Fn 14) polypeptide.
  • Fn 14 soluble TWEAK receptor
  • An example of a soluble form of the TWEAK receptor is an Fc fusion protein that includes at least a portion of the extracellular domain of Fn14 referred to as Fn14-Fc.
  • Fn14-Fc Fn14-Fc
  • Other soluble forms of Fn14, e.g., forms that do not include an Fc domain, may also be used in the methods of the invention.
  • the TWEAK antagonist is administered via an enteric route.
  • the tissue to be targeted with radiation therapy can be gastrointestinal tissue or is proximal to gastrointestinal tissue.
  • the TWEAK antagonist is administered via a parenteral route.
  • the TWEAK antagonist can be delivered to the tissue which will be targeted with radiation therapy.
  • the localized delivery is performed via local injection.
  • the localized delivery is performed via ultrasound-mediated microbubble destruction.
  • FIG. 2 shows the genomic loci for TWEAK WT and mutants, indicating the WT locus, neomycin-containing targeting construct, and neo-deleted locus.
  • the coding exons are shown as black boxes.
  • the arrow indicates the direction of transcription.
  • the targeting construct contains a human CD2 expression cassette (grey box) and a loxP-flanked neomycin cassette (striped box flanked by solid black).
  • the CD2 cassette and one loxP element remain.
  • Bold lines (5' and 3') beneath the WT genomic locus mark the positions of external Southern blot probes.
  • Figure 3 shows Northern blot analysis of tissues from TWEAK KO and WT mice. Fifteen ⁇ g of RNA from the indicated tissues were probed for GAPDH or TWEAK, using the full-length TWEAK cDNA.
  • FIG. 4 shows mRNA expression of TWEAK locus neighbors Senp3 (SMT3IP1), Tnfs13 (APRIL) and Eif4a by gene array analysis of colon tissue from TWEAK KO and WT Balb/c mice. Averages for 3 animals per group are plotted with no significant differences.
  • Figure 5 shows the spleen weight and spleen weight to body weight ratio for 4 or 12 month old TWEAK KO and WT mice (WT open bars, KO filled bars).
  • Figure 6 shows the numbers of cells in CD3, CD4, and CD8 T cell subsets from the spleens of TWEAK KO and WT mice. Twelve-month-old mice were used to measure cell numbers.
  • Figure 7 shows the number of cells in IgM+ B cell, NK cell, and NKT cell subsets from the spleens of TWEAK KO and WT mice.
  • Four-month-old mice were used to measure NK and NKT cells, and 12-month-old mice were used to measure IgM+ B cells.
  • Figure 8 shows the levels of activated/memory cells within the CD4 and CD8 spleen T cell populations from twelve-month old animals. All error bars are SEM, 5-7 mice per group were used for the comparisons.
  • Figures 9A and 9E are photos of isolated colons of WT and TWEAK KO mice, respectively.
  • Figure 9B-9D and 9F-9H show histological features of Balb/c WT and TWEAK KO colons: untreated 9B WT and 9F KO at day 0 of the TNBS colitis protocol; TWEAK WT 9C 1 9D and KO 9G, 9H at day 10 of the colitis protocol.
  • Scale bars in Figures 9B, 9C, 9F, and 9G correspond to 0.1 mm.
  • the images in Figures 9D and 9H are two fold higher magnification.
  • Figure 11 shows mean weight loss +/- SEM in TWEAK KO and WT mice after TNBS treatment on days 0 and 7 (indicated by arrows). The number of WT and KO mice for each time point are in parentheses. Asterisks indicate significant differences (p ⁇ 0.05, unpaired t-test) on days 1 , 3 and 5.
  • Figure 15 shows histological scores for TNBS colitis in TWEAK KO, Fn14 KO and WT mice on the C57BL/6 background.
  • Figure 21 shows the anti-TNP response of sacral lymph node T cells of TNBS-induced colitis mice on day 10 following TNBS administration. Stimulation index was calculated as the level of in vitro 3 H- thymidine incorporation compared to cultures without antigen. WT group is smaller due to the death of 3 mice during the course of the experiment.
  • Figure 21 shows the anti-TNP serum IgG titer on day 10 of TNBS colitis. No significant differences were observed.
  • Figure 22 depicts caspase-3 activation detected by western blot of Balb/c WT and Fn14 KO mouse intestinal epithelial cell samples treated TNF ⁇ .
  • Figure 23 shows representative images of single staining with anti- TWFJAK and epithelial marker EpCAM on serial colon sections from Balb/c WT and TWEAK KO mice, naive or 3 days after TNBS administration to induce colitis.
  • Anti-TWEAK staining of TWEAK KO serves as a control and reflects a low level of nonspecific staining.
  • Figure 24 shows anti-Fn14 immunofluorescent staining (green) of epithelial colon sections from Balb/c WT and Fn14 KO mice, naive (top row) or 3 days after TNBS administration to induce colitis. Edges of the tissue on the lumen side showed nonspecific staining in both WT and Fn 14 KO mice. The bottom image shows immunofluorescent staining for both Fn14 (green) and F4/80 (red) in WT mouse tissue 3 days after TNBS administration.
  • Figure 25 shows representative images of anti-Fn14 double staining with epithelial marker EpCAM or macrophage marker F4/80 on epithelial colon sections from WT and Fn 14 KO mice 3 days after TNBS colitis.
  • Figure 26 shows the Fn14 mRNA relative expression values for primary colon tissue cultures with media or CpG ODN or TNF ⁇ stimuli as shown. Each line represents a culture from an individual mouse.
  • Figure 27 shows a flow cytometry overlay of anti-Fn14 (open profile) vs. control Ig staining (filled profile) of epithelial cell line MODE-K.
  • Figure 28 shows MMP-9 production by MODE-K cells cultured in media alone or in the presence of TWEAK (1.0 ng/ml), TWEAK plus soluble Fn14 decoy protein (10 ⁇ g/ml), of agonistic anti-Fn14 mAb (10 ⁇ g/ml), or control Ig (10 ⁇ g/ml).
  • Figure 29 shows MCP-1 and KC production in MODE-K cells stimulated by agonistic anti-Fn14 mAb versus control Ig. Mean values +/- SD are shown for triplicate cultures. Asterisks indicate significant differences, all p values ⁇ 0.005 by Student's t test.
  • Figure 32 shows the TNBS-induced colitis histology scores of WT mice, TWEAK KO mice, WT mice treated with control Ig, and WT mice treated with anti-TWEAK monoclonal antibody three and ten days after administration of TNBS. Antibodies were injected on day 0, day 3, and day 7 of TNBS-induced colitis.
  • Figure 33 shows representative images of H&E-stained jejunum and colon samples from Balb/c WT and TWEAK-KO mice 24 hours after receiving 3 Gy of whole body irradiation. Apoptotic cells with dense chromatin masses are indicated by arrows.
  • Figure 34 shows a plot of the number of apoptotic cells observed in the jejunum and colon of Balb/c WT and TWEAK-KO mice 24 hours after receiving 3 Gy of whole-body ⁇ -irradiation.
  • Figure 35 shows a plot of the percentage of apoptotic cells at various crypt cell positions along the longitudinal crypt axis in Balb/c WT (dark circles) and TWEAK-KO mice (gray squares) 24 hours after receiving 3 Gy of whole-body ⁇ -irradiation.
  • Figure 36 shows a plot of the percentage of apoptotic cells at various crypt cell positions along the longitudinal crypt axis in C57BL6 WT (dark circles) and Fn-14-KO mice (gray squares) 24 hours after receiving 3 Gy of whole- body ⁇ -irradiation.
  • Figure 37 shows representative images of H&E stained jejunum and ileum samples from Balb/c WT and TWEAK-KO mice 24 hours after receiving 12 Gy of whole body ⁇ -irradiation. Regenerating microcolonies of cells are indicated with arrows.
  • Figure 38 shows a plot of the numbers of regenerating microcolonies of cells in jejunum, ileum, and colon samples from Balb/c WT and TWEAK-KO mice 4 days after receiving 12 Gy of whole body ⁇ -irradiation.
  • Figure 39 shows a plot of the number of BrdU + cells in jejunum samples of Balb/c WT or TWEAK-KO mice or in C57BL6 WT or Fn 14-KO mice 24 hours after receiving 3 Gy of whole-body ⁇ -irradiation.
  • the invention provides methods of preventing tissue damage induced by radiation therapy. Aspects of the invention relate, in part, to the discovery that disrupting the signaling of TNF family member TWEAK (TNF-like weak inducer of apoptosis) through its receptor, Fn14, reduces levels of epithelial cell death and increases epithelial cell regeneration following radiation treatment in a mouse model of tissue injury by ⁇ -irradiation.
  • Embodiments of the invention encompass the use of an antagonist of TWEAK for preventing or reducing cell death that occurs as a result of radiation therapy or radiation exposure.
  • the methods comprise administering to a subject who has received, is receiving, or will receive radiation therapy a therapeutically effective amount of a TWEAK antagonist sufficient to prevent or reduce the severity of radiation-induced cell death.
  • a therapeutically effective amount of a TWEAK antagonist sufficient to prevent or reduce the severity of radiation-induced cell death is meant an amount of a TWEAK antagonist delivered to a subject that reduces the levels of apoptosis (programmed cell dea + h) occurring in an area of tissue treated with radiation therapy or otherwise exposed to radiation to a level that is either 1) not detectably different than that occurring in the tissue prior to administration of the radiation, or 2) that is decreased relative to the level of apoptosis occurring in the tissue receiving radiation when a TWEAK antagonist is not administered to the subject.
  • apoptosis programmed cell dea + h
  • the method of preventing or reducing cell death that occurs as a result of radiation therapy comprises 1) administering a TWEAK antagonist and 2) administering radiation.
  • the TWEAK antagonist is administered a sufficient amount of time prior to administration of radiation to allow the TWEAK antagonist to penetrate into the target tissue.
  • the TWEAK antagonist is administered at least two hours before administration of the radiation.
  • the TWEAK antagonist is administered between two to four hours prior to administration of the radiation.
  • the time between the administration of a TWEAK antagonist and subsequent administration of radiation is four to six hours, six to eight hours, eight to ten hours, ten to twelve hours, twelve to twenty-four hours, twenty-four to forty-eight hours, or more than 48 hours.
  • the TWEAK antagonist is administered prior to multiple rounds of radiation treatment. In other embodiments, the TWEAK antagonist is administered prior to each round of radiation administered over the course of the patient's treatment. In some embodiments, the TWEAK antagonist is administered in repeat doses. In further embodiments, the TWEAK antagonist is administered in repeat doses prior to multiple rounds of radiation treatment. In further embodiments, the TWEAK antagonist is administered in repeat doses for every round of radiotherapy administered over the course of the patients treatment.
  • the TWEAK antagonist is administered to a subject before and after radiation treatment. In further embodiments, the TWEAK antagonist is administered to a subject before, during, and after a course of radiation therapy. In some embodiments, the dosage of the TWEAK antagonist is relatively high just before and after radiation treatment and is then lowered to smaller doses over time following the treatment.
  • the TWEAK antagonist is administered to a subject after exposure to radiation.
  • exposure to radiation includes radiation therapy, accidental radiation exposure, and exposure to individuals at risk for radiation exposure. Accordingly, the methods can benefit individuals who are exposed to radiation inadvertantly or who are exposed to radiation as part of their work, including, for example, individuals working in nuclear power plants or nuclear fuel and/or nuclear waste processing facilities, individuals transporting nuclear material, researchers working with radioactive materials, individuals responsible for handling hazardous materials, members of the military, medical care workers, and the like.
  • the subject is a patient receiving X-rays for purposes of medical monitoring and/or diagnosis.
  • the TWEAK antagonist is administered to a subject following inadvertant exposure to radiation.
  • the TWEAK antagonist can be administered in single or multiple doses within a few hours after exposure to radiation. In some embodiments, the TWEAK antagonist is administered within 24 hours of exposure to radiation. In further embodiments, the antagonist is administered within 48 hours, 72 hours, or 96 hours or more following exposure to radiation. Administration of a TWEAK antagonist following exposure to radiation can be continued for several days, weeks, or months, or as long as the administration may be therapeutically effective. In some embodiments, the dosage of a TWEAK antagonist is lowered from a higher dose immediately following exposure to radiation to a lower dose over the course of several days, weeks, or months.
  • the TWEAK antagonist is administered in a single dose. In some embodiments, the antagonist is administered in multiple doses. In some embodiments, the TWEAK antagonist is administered several times per day, i.e. once every two to three hours, three to six hours, six to nine hours, or nine to twelve or more hours.
  • the methods of the invention are used to prevent or reduce the severity of radiation-induced cell death in a subject with cancer.
  • the cancer can be, for example, a carcinoma, sarcoma, lymphoma, leukemia, myeloma, germ cell tumor, or blastoma.
  • Carcinomas are malignant tumors derived from epithelial cells. Carcinomas are the most common cancers, and include common forms of lung, colon, breast, and prostate cancer.
  • Sarcomas are malignant tumors derived from connective tissue or mesenchymal cells (bone, cartilage, or fat).
  • Lymphomas, leukemias, and myelomas are malignancies derived from hematopoietic (blood-forming) cells, including bone marrow cells and lymphocytes.
  • Germ cell tumors are derived from totipotent cells. In adults, germ cell tumors are most often found in the testicle and ovary. In fetuses, infants, and young children, germ cell tumors are most often found on the body midline, particularly at the tip of the tailbone. Blastomas are tumors that resemble an immature or embryonic tissue, and the majority are typically found in children.
  • the cancer is a solid cancer.
  • the cancer can be, for example, lung cancer, prostate cancer, breast cancer, colon or rectal cancer, bladder cancer, pancreatic cancer, endometrial cancer, ovarian cancer, testicular cancer, melanoma, nonmelanoma skin cancer, cervical cancer, small bowel cancer, stomach cancer, urinary tract cancer, thyroid cancer, kidney (renal cell) cancer, neuroblastoma, rhabdomyosarcoma (arising from muscle), retinoblastoma, osteosarcoma, Ewing's sarcoma, and teratoma.
  • the cancer is a hematological neoplasm.
  • the hematological neoplasm is a leukemia, lymphoma, or multiple myeloma.
  • the subject receiving radiation therapy has a non-malignant condition.
  • non-malignant conditions include trigeminal neuralgia, severe thyroid eye disease, pterygium, pigmented villonodular synovitis, keloid scar growth, and heterotopic ossification.
  • the subject receives total body irradiation (TBI) as part of the preparative regimen for a hematopoietic stem cell (or bone marrow) transplantation due to a disease of the blood, bone marrow, or because of a certain type of cancer.
  • TBI total body irradiation
  • TBI treatment typically is delivered twice daily over 3 days. However, a variety of other approaches may be used depending on the tumor site and the individual protocol.
  • a current multiple myeloma TBI regimen for example, utilizes a single fraction of 2 grays (Gy). In most TBI protocols, however, the total dose is 12 Gy.
  • the radiation therapy is palliative radiation therapy.
  • Palliative radiation therapy is therapy that is not curative, but rather is used to control symptoms associated with localized tumors that cannot be treated by other methods, such as surgery.
  • the radiation therapy is prophylactic radiation therapy.
  • prophylactic radiation may be given to areas that do not have evidence of cancer. This is done to prevent cancer cells from growing in the area receiving the radiation.
  • prophylactic radiation to the contralateral breast can be administered to reduce the rate of subsequent contralateral breast cancer and offer an option for risk reduction in women with BRCA germline mutations.
  • prophylactic radiation can be administered to the central nervous system (whole brain irradiation, also called prophylactic cranial irradiation, or PCI).
  • the methods prevent or reduce the severity of radiation-induced cell death of epithelial cells.
  • Apoptosis or programmed cell death, is an important physiological process in epithelia for eliminating senescent, damaged, redundant, or deleterious cells.
  • Epithelial cells line the cavities and surfaces of structures throughout the body. The outermost layer of skin is composed of dead stratified squamous, keratinized epithelial cells.
  • the tissues that line the inside of the mouth, the esophagus, and part of the rectum are composed of nonkeratinized stratified squamous epithelium.
  • the methods of the invention prevent or reduce the severity of radiation induced cell death of non-keratinized stratified squamous epithelium. In other embodiments, the methods of the invention prevent or reduce the severity of radiation induced cell death of simple squamous, columnar, or pseud ostratified epithelial cells. In some embodiments, the methods of the invention prevent or reduce the severity of radiation induced cell death of endothelial or mesothelial cells.
  • the methods of the invention prevent or reduce the severity of radiation-induced cell death of gastrointestinal (Gl) epithelial cells.
  • the Gl epithelial cells are cells of the mouth, larynx, or esophagus.
  • the Gl epithelial cells are cells of the stomach, duodenum, jejunum, ileum, cecum, colon, or rectum. TWEAK signaling and TWEAK antagonists
  • TNF superfamily of ligands and receptors are prominent regulators of cell fate decisions including survival, proliferation, and differentiation (Ware et al., Cytokine Growth Factor Rev. 14:181-4 (2003)). They play- essential roles in the organogenesis and homeostasis of multiple systems, including bone, skin appendages such as hair and teeth, and lymphoid tissues. They also play complex immunoregulatory roles, for example in host defense, inflammatory responses, and positive and negative regulation of adaptive immunity.
  • TWEAK a member of the TNF ligand superfamily
  • TNF ligand superfamily is a type II- transmembrane protein that can be cleaved to function as a soluble cytokine and is highly expressed by inflammatory cells (Chicheportiche et al., J. Biol. Chem. 272: 32401-10 (1997)).
  • the TWEAK receptor, Fn14 is a TNF receptor superfamily member expressed by nonlymphoid cell types. TWEAK was first described as a weak inducer of apoptosis (Chicheportiche et al., J. Biol. Chem.
  • Fn14 is expressed by many tissue-resident progenitor cells (Girgenrath et al., EMBO J. 25:5826-39 (2006)); Jakubowski et al., J. Clin. Invest, 115:2330 ⁇ 0 (2005); Perper et al., J. Immunol. 177:2610-20 (2006)).
  • TWEAK is a multifunctional cytokine, similar in this regard to its sibling TNF. TWEAK functions physiologically after acute injury and pathologically in chronic inflammatory disease settings. In contrast to TNF however, TWEAK plays no apparent role in development or homeostasis.
  • TWEAK antagonists used to prevent or reduce the severity of radiation-induced cell death includes, e.g., small organic or inorganic molecules, nucleic acids, proteins, or peptide mimetics that are capable of interrupting the binding of TWEAK to its cognate receptor Fn14 or otherwise interfere with TWEAK receptor signaling.
  • TWEAK receptor signaling refers to all molecular reactions associated with the TWEAK receptor pathway and subsequent molecular reactions which result therefrom.
  • TWEAK antagonists useful in preventing or reducing radiation- induced cell death are known in the art. Such agents include those disclosed in, e.g. International Publication Numbers WO 98/05783, WO 98/35061 , WO 99/19490, WO 00/42073, and WO 01/45730, all of which are incorporated herein by reference in their entirety.
  • the antagonist is a biologic, e.g., a protein having a molecular weight of between 5-300 kDa.
  • a TWEAK antagonist may inhibit binding of TWEAK to a Fn14.
  • a typical TWEAK antagonist can bind to TWEAK or a TWEAK receptor, e.g., Fn14.
  • a TWEAK antagonist that binds to TWEAK or Fn14 may block the binding site on TWEAK or Fn14, alter the conformation of TWEAK or Fn14, or otherwise decrease the affinity of TWEAK for Fn14 or prevent the interaction between TWEAK and Fn14.
  • a TWEAK antagonist may bind to TWEAK or to Fn14 with a K d of less than 10 ⁇ 6 , 10 "7 , 10 '8 , 10 "9 , or 10 "10 M.
  • the antagonist binds to TWEAK with an affinity at least 5, 10, 20, 50, 100, 200, 500, or 1000-fold higher than its affinity for TNF or another TNF superfamily member (other than TWEAK).
  • the antagonist binds to the Fn14 with an affinity at least 5, 10, 20, 50, 100, 200, 500, or 1000-fold better than its affinity for the TNF receptor or a receptor for another TNF superfamily member.
  • Exemplary TWEAK antagonists include antibodies (e.g., monoclonal antibodies) that bind to TWEAK or Fn14 and soluble forms of Fn14 that compete with cell surface Fn14 for binding to TWEAK.
  • Other types of antagonists e.g., small molecules, nucleic acid or nucleic acid-based aptamers, and peptides, can be isolated by screening, e.g., as described in Jhaveri et al. Nat. Biotechnol. 18:1293-1297 (2000) and U.S. Patent No. 5,223,409.
  • the TWEAK antagonists used in the methods of the invention include antibodies that bind to TWEAK and/or Fn14.
  • Antibodies directed to TWEAK or a TWEAK receptor that are useful in the invention are described herein and are known in the art. Exemplary antibodies are described, e.g., in International Patent Publication No. WO 2006/130374 and U.S. Patent Publication No. 2008/0279853, which are incorporated herein by reference in their entirety.
  • antibody refers to a protein that includes at least one immunoglobulin variable region, e.g., an amino acid sequence that provides an immunoglobulin variable domain or an immunoglobulin variable domain sequence.
  • Antigen-binding fragments of antibodies include, e.g., single chain antibodies, Fab fragments, F(ab')2 fragments, Fd fragments, Fv fragments, and dAb fragments.
  • Complete antibodies include, e.g., intact and/or full length immunoglobulins of types IgA, IgG (e.g., IgGI, lgG2, lgG3, lgG4), IgE, IgD, IgM (as well as subtypes thereof).
  • the light chains of the immunoglobulin may be of types kappa or lambda.
  • An antibody can be functional for antibody-dependent cytotoxicity and/or complement-mediated cytotoxicity, or may be non-functional for one or both of these activities.
  • the VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), referenced above, interspersed with regions that are more conserved, termed "framework regions" (FR).
  • CDR complementarity determining regions
  • FR framework regions
  • the extent of the FR's and CDR's has been precisely defined (see, Kabat, E. A., et al., Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No.
  • Each VH and VL is typically composed of three CDR's and four FR 1 s, arranged from amino-terminus to carboxyl-terminus in the following order: FR1 , CDR1 , FR2, CDR2, FR3, CDR3, FR4.
  • an "immunoglobulin domain” refers to a domain from the variable or constant domain of immunoglobulin molecules. Immunoglobulin domains typically contain two beta- sheets formed of about seven beta-strands, and a conserved disulphide bond (see, e.g., A. F. Williams and A. N. Barclay, Ann. Rev Immunol. 6:381-405 (1988)).
  • An "immunoglobulin variable domain sequence” refers to an amino acid sequence that can form a structure sufficient to position CDR sequences in a conformation suitable for antigen binding. For example, the sequence may include all or part of the amino acid sequence of a naturally occurring variable domain.
  • the sequence may omit one, two or more N- or C-terminal amino acids, internal amino acids, may include one or more insertions or additional terminal amino acids, or may include other alterations.
  • a polypeptide that includes an immunoglobulin variable domain sequence can associate with another immunoglobulin variable domain sequence to form a target binding structure (or "antigen binding site"), e.g., a structure that interacts with TWEAK or Fn 14. - ⁇ -
  • the VH or VL chain of the antibody can further include all or part of a heavy or light chain constant region, to thereby form a heavy or light immunoglobulin chain, respectively.
  • the antibody is a tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains.
  • the heavy and light immunoglobulin chains can be connected by disulfide bonds.
  • the heavy chain constant region typically includes three constant domains, CH1 , CH2, and CH3.
  • the light chain constant region typically includes a CL domain.
  • the variable region of the heavy and light chains contain a binding domain that interacts with an antigen.
  • the constant regions of the antibodies typically mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
  • One or more regions of an antibody can be human, effectively human, or humanized, as described below.
  • one or more of the variable regions can be human or effectively human.
  • An "effectively human" immunoglobulin variable region is an immunoglobulin variable region that includes a sufficient number of human framework amino acid positions such that the immunoglobulin variable region does not elicit an immunogenic response in a normal human.
  • An "effectively human” antibody is an antibody that includes a sufficient number of human amino acid positions such that the antibody does not elicit an immunogenic response in a normal human.
  • one or more of the CDRs can be human.
  • Each of the light chain CDRs can be human.
  • HC CDR3 can be human.
  • One or more of the framework regions can be human, e.g., FRI, FR2, FR3, and FR4 of the HC or LC. In one embodiment, all the framework regions are human, e.g., derived from a human somatic cell, e.g., a hematopoietic cell that produces immunoglobulins or a non- hematopoietic cell.
  • the human sequences are germline sequences, e.g., encoded by a germline nucleic acid.
  • One or more of the constant regions can be human, effectively human, or humanized.
  • at least 70, 75, 80, 85, 90, 92, 95, or 98% of the framework regions (e.g., FR1 , FR2, and FR3, collectively, or FR1 , FR2, FR3, and FR4, collectively) or the entire antibody can be human, effectively human, or humanized.
  • FR1 , FR2, and FR3 collectively can be at least 70, 75, 80, 85, 90, 92, 95, 98, or 99% identical, or completely identical, to a human sequence encoded by a human germline segment.
  • a "humanized" immunoglobulin variable region is an immunoglobulin variable region that is modified such that the modified form elicits less of an immune response in a human than does the non-modified form, e.g., is modified to include a sufficient number of human framework amino acid positions such that the immunoglobulin variable region does not elicit an immunogenic response or elicits a reduced immunogenic response in a normal human as compared to a non-humanized antibody.
  • humanized immunoglobulins include, for example, U.S. Patent Numbers 6,407,213 and 5,693,762.
  • humanized immunoglobulins can include a non-human amino acid at one or more framework amino acid positions.
  • Exemplary humanized antibodies that bind to TWEAK are described below as huP2D10-1 and huP2D10-2.
  • the antibodies can be conjugated to a moiety, e.g., can be conjugated to poly(ethylene glycol) (e.g., PEGylated), e.g., to reduce the immunogenicity and/or increase the circulating half-lives of antibodies.
  • the antibody inhibits the interaction between TWEAK and Fn14, e.g., by physically blocking the interaction, decreasing the affinity of TWEAK and/or Fn14 for its counterpart, reducing the signaling activity of Fn14, disrupting or destabilizing TWEAK/Fn14 complexes, sequestering TWEAK or Fn14, or targeting TWEAK or Fn14 for degradation.
  • the antibody can bind to TWEAK or Fn14 at one or more amino acid residues that participate in the TWEAK/ Fn14 binding interface. Such amino acid residues can be identified, e.g., by alanine scanning.
  • the antibody can bind to residues that do not participate in the TWEAK/ Fn14 binding.
  • the antibody can alter a conformation of TWEAK or Fn 14 and thereby reduce binding affinity, or the antibody may sterically hinder TWEAK/ Fn14 binding.
  • the antibody can prevent activation of a TWEAK/ Fn14 mediated event or activity (e.g., NF- ⁇ B activation).
  • the TWEAK antagonist used in the methods of the invention is an anti-TWEAK antibody.
  • the TWEAK antagonist is an anti- Fn 14 antibody.
  • the sequence of an exemplary human TWEAK to which anti-TWEAK antibodies may be directed is shown in SEQ ID NO:1.
  • the sequence of a mouse TWEAK is shown in SEQ ID NO:2.
  • International Patent Application No. WO 2006/130374 discloses the sequences of specific examples of anti-TWEAK antibodies that are useful in the methods of the invention, such as P2D10, huP2D10-1 , and huP2D10-2.
  • amino acid sequence of the IgG heavy chain in each of mature huP2D10-1 and huP2D10-2 antibodies is as follows (SEQ ID NO:3):
  • amino acid sequence of the light chain of huP2D10-1 is as follows (SEQ ID NO:4): 1 DWMTQSPLS LPVTPGEPAS ISCRSSQSLV SSKGNTYLHW YLQKPGQSPQ 51 FLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YFCSQSTHFP 101 RTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASWCL LNNFYPREAK 151 VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 201 VTHQGLSSPV TKSFNRGEC
  • amino acid sequence of the light chain of huP2D10-2 is as follows (SEQ ID NO:5):
  • Suitable antibodies for use in the methods of the invention include an antibody that can bind to an epitope on TWEAK which includes at least one, two, three or four amino acid residues from an epitope on TWEAK recognized by P2D10, to a peptide from TWEAK that is bound by P2D10 (e.g., a peptide less than 25, 20, or 15 amino acids in length) or to a region of TWEAK recognized by P2D10.
  • the antibody may specifically bind to an epitope, e.g., a linear or a conformational epitope, of TWEAK, in particular human TWEAK, e.g., the soluble region of TWEAK.
  • the antibody may compete with P2D10 for binding to TWEAK, e.g., to human TWEAK.
  • the antibody may competitively inhibit binding of P2D10 to TWEAK, e.g., human TWEAK.
  • the antibody may bind to an epitope which overlaps with that of P2D10, e.g., includes at least one, two, three or four amino acids in common with the P2D10 epitope, or an epitope which, when bound, sterically prevents TWEAK interaction with P2D10.
  • the antibody specifically binds to at least a part of the interaction site on TWEAK that contacts human Fn 14.
  • the antibody may compete with Fn14 for binding to TWEAK, e.g., to human TWEAK.
  • the antibody may competitively inhibit binding of Fn 14 to TWEAK.
  • the antibody may interact with an epitope on TWEAK which, when bound, sterically prevents interaction between TWEAK and Fn14 (e.g., between human TWEAK and human Fn14).
  • the protein includes at least one, two and preferably three CDRs from the light or heavy chain variable region of P2D10.
  • CDRs refer to CDRs as defined by Chothia's hypervariable loops.
  • the protein includes, in the heavy chain variable domain sequence, at least one, two, or three of the following sequences within a CDR region:
  • VLYYDYDGDRIEVMDY CDR3 (SEQ ID NO:8), or a CDR having an amino acid sequence that differs by no more than 4, 3, 2.5, 2, 1.5, 1 , or 0.5 alterations (e.g., substitutions, insertions or deletions) for every 10 amino acids (e.g., the number of differences being proportional to the CDR length) relative to a sequence listed above, e.g., at least one alteration but not more than two, three, or four per CDR.
  • the heavy chain variable domain sequence may include these CDR sequences particularly in CDR3, or in at least two CDRs, e.g., CDR1 and CDR3, CDR2 and CDR3, or in all three CDRs.
  • the protein can include, in the heavy chain variable domain sequence, at least one, two, or three of the following sequences within a CDR region (amino acids in parentheses represent alternatives for the particular position):
  • the antibody can include, in the light chain variable domain sequence, at least one, two, or three of the following sequences within a CDR region:
  • SQSTHFPRT SEQ IDNO:14
  • CDR3 SQSTHFPRT (SEQ IDNO:14); (CDR3), or a CDR having an amino acid sequence that differs by no more than 4, 3, 2.5, 2, 1.5, 1 , or 0.5 alterations (e.g., substitutions, insertions or deletions) for every 10 amino acids (e.g., the number of differences being proportional to the CDR length) relative to a sequence listed above, e.g., at least one alteration but not more than two, three, or four per CDR.
  • the light chain variable domain sequence may include these CDR sequences particularly in CDR3, or in at least two CDRs, e.g., CDR1 and CDR3, CDR2 and CDR3, or in all three CDRs.
  • the antibody can include, in the light chain variable domain sequence, at least one, two, or three of the following sequences within a CDR region (amino acids in parentheses represent alternatives for the particular position): (i) (RK)-S-S-Q-S-(LI)-(KV)-S-S-(KR)-G-N-(TN)-Y-L-(EHDNQY) (SEQ ID NO: 15), or (RK)-S-S-Q-S-(LI)-V-S-S-(KR)-G-N-(TN)-Y-L-H (SEQ ID NO: 16);
  • the antibody includes all six CDRs from P2D10 or closely related CDRs, e.g., CDRs which are identical or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions), or other CDR described herein.
  • the antibody includes at least one, two, or three CDRs that have the same canonical structures and the corresponding Chothia CDRs of P2D10, e.g., the same canonical structures as at least CDR1 and/or CDR2 of the heavy and/or light chain variable domains of P2D10.
  • antibodies such as these, can be made, for example, by preparing and expressing synthetic genes that encode the recited amino acid sequences or by mutating human germline genes to provide a gene that encodes the recited amino acid sequences.
  • Antibodies that bind to TWEAK or Fn14 may also be generated by a variety of other means. (See, for example, "Antibodies: A Laboratory Manual,” ed. by Harlow and Lane, Cold Spring Harbor press: 1988).
  • One exemplary method includes screening protein expression libraries, e.g., phage or ribosome display libraries.
  • Phage display is described, for example, U.S. 5,223,409; Smith, Science 228:1315-1317 (1985); WO 92/18619; WO 91/17271 ; WO 92/20791 ; WO 92/15679; WO 93/01288; WO 92/01047; WO 92/09690; and WO 90/02809.
  • the display of Fab's on phage is described, e.g., in U.S. Pat. Nos. 5,658,727; 5,667,988; and 5,885,793.
  • TWEAK- or Fn14-binding antibody In addition to the use of display libraries, other methods can be used to obtain a TWEAK- or Fn14-binding antibody.
  • all or part of TWEAK or Fn14 may be used as an immunogen or as a target for selection.
  • the immunized animal contains immunoglobulin-producing cells with natural, human, or partially human immunoglobulin loci.
  • the non-human animal includes at least a part of a human immunoglobulin gene. For example, it is possible to engineer mouse strains deficient in mouse antibody production with large fragments of the human Ig loci. Using the hybridoma technology, antigen-specific monoclonal antibodies derived from the genes with the desired specificity may be produced and selected.
  • Non-human antibodies to TWEAK or Fn14 can also be produced, for example, in a rodent.
  • the non-human antibody can be humanized, e.g., as described in EP 239 400; U.S. Pat. Nos. 6,602,503; 5,693,761 ; and 6,407,213, deimmunized, or otherwise modified to make it effectively human.
  • EP 239 400 (Winter et al.) describes altering antibodies by substitution (within a given variable region) of their complementarity determining regions (CDRs) for one species with those from another.
  • CDRs of a non-human (e.g., murine) antibody are substituted into the corresponding regions in a human antibody, e.g., from germline immunoglobulin genes, by using recombinant nucleic acid technology to produce sequences encoding the desired substituted antibody.
  • Human constant region gene segments of the desired isotype usually gamma I for CH and kappa for CL
  • the humanized heavy and light chain genes can be co-expressed in mammalian cells to produce soluble humanized antibody.
  • a non-human TWEAK- or Fn14 binding antibody may be modified by specific deletion of human T cell epitopes or "deimmunization" by the methods disclosed in WO 98/52976 and WO 00/34317. Briefly, the heavy and light chain variable regions of an antibody can be analyzed for peptides that bind to MHC Class II; these peptides represent potential T-cell epitopes (as defined in WO 98/52976 and WO 00/34317).
  • peptide threading For detection of potential T-cell epitopes, a computer modeling approach termed "peptide threading" can be applied, and in addition a database of human MHC class Il binding peptides can be searched for motifs present in the VH and VL sequences, as described in WO 98/52976 and WO 00/34317. These motifs bind to any of the 18 major MHC class Il DR allotypes, and thus constitute potential T cell epitopes.
  • Potential T-cell epitopes detected can be eliminated by substituting small numbers of amino acid residues in the variable regions, or preferably, by single amino acid substitutions. As far as possible, conservative substitutions are made. Often, but not exclusively, an amino acid common to a position in human germline antibody sequences may be used.
  • nucleic acids encoding VH and VL can be constructed by mutagenesis or other synthetic methods (e.g., de novo synthesis, cassette replacement, and so forth).
  • a mutagenized variable sequence can, optionally, be fused to a human constant region, e.g., human IgGI or kappa constant regions.
  • a potential T cell epitope will include residues which are known or predicted to be important for antibody function. For example, potential T cell epitopes are usually biased towards the CDRs. In addition, potential T cell epitopes can occur in framework residues important for antibody structure and binding. Changes to eliminate these potential epitopes will in some cases require more scrutiny, e.g., by making and testing chains with and without the change. Where possible, potential T cell epitopes that overlap the CDRs can be eliminated by substitutions outside the CDRs. In some cases, an alteration within a CDR is the only option, and thus variants with and without this substitution can be tested.
  • the substitution required to remove a potential T cell epitope is at a residue position within the framework that might be critical for antibody binding, hi these cases, variants with and without this substitution are tested.
  • variants with and without this substitution are tested.
  • several variant deimmunized heavy and light chain variable regions are designed and various heavy/light chain combinations are tested to identify the optimal deimmunized antibody.
  • the choice of the final deimmunized antibody can then be made by considering the binding affinity of the different variants in conjunction with the extent of deimmunization, particularly, the number of potential T cell epitopes remaining in the variable region.
  • Deimmunization can be used to modify any antibody, e.g., an antibody that includes a non-human sequence, e.g., a synthetic antibody, a murine antibody other non-human monoclonal antibody, or an antibody isolated from a display library.
  • a non-human sequence e.g., a synthetic antibody, a murine antibody other non-human monoclonal antibody, or an antibody isolated from a display library.
  • the antibody can include a human Fc region, e.g., a wild-type Fc region or an Fc region that includes one or more alterations.
  • the constant region is altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function).
  • the human IgGI constant region can be mutated at one or more residues, e.g., one or more of residues 234 and 237.
  • Antibodies may have mutations in the CH2 region of the heavy chain that reduce or alter effector function, e.g., Fc receptor binding and complement activation.
  • antibodies may have mutations such as those described in U.S. Patent Nos. 5,624,821 and 5,648,260.
  • Antibodies may also have mutations that stabilize the disulfide bond between the two heavy chains of an immunoglobulin, such as mutations in the hinge region of lgG4, as disclosed in the art (e.g., Angal et al., MoI. Immunol. 30:105-08 (1993)). See also, e.g., U.S. 2005-0037000.
  • Fully human monoclonal antibodies that bind to a TWEAK receptor can be produced, e.g., using in wYro-primed human splenocytes, as described by Boerner et al., J.
  • phage display libraries may also be used to isolate high affinity antibodies that can be developed as human therapeutics using standard phage technology (see, for example, Hoogenboom et al., Immunotechnology, 4:1-20 (1998); Hoogenboom et al., Immunol Today, 2: 371-378 (2000); and U.S. Patent Publication No. 2003/0232333).
  • An anti-TWEAK or anti-Fn14 antibody may be modified, e.g., by mutagenesis, to provide a pool of modified antibodies for use in the methods of the invention.
  • the modified antibodies are evaluated to identify one or more antibodies which have altered functional properties (e.g., improved binding, improved stability, reduced antigenicity, or increased stability in vivo).
  • display library technology is used to select or screen the pool of modified antibodies. Higher affinity antibodies are then identified from the second library, e.g., by using higher stringency or more competitive binding and washing conditions. Other screening techniques can also be used.
  • the mutagenesis is targeted to regions known or likely to be at the binding interface. If, for example, the identified binding proteins are antibodies, then mutagenesis can be directed to the CDR regions of the heavy or light chains as described herein. Further, mutagenesis can be directed to framework regions near or adjacent to the CDRs, e.g., framework regions, particularly within 10, 5, or 3 amino acids of a CDR junction. In the case of antibodies, mutagenesis can also be limited to one or a few of the CDRs, e.g., to make step-wise improvements.
  • mutagenesis is used to make an antibody more similar to one or more germline sequences.
  • One exemplary germlining method can include: identifying one or more germline sequences that are similar (e.g., most similar in a particular database) to the sequence of the isolated antibody. Then mutations (at the amino acid level) can be made in the isolated antibody, either incrementally, in combination, or both. For example, a nucleic acid library that includes sequences encoding some or all possible germline mutations is made. The mutated antibodies are then evaluated, e.g., to identify an antibody that has one or more additional germline residues relative to the isolated antibody and that is still useful (e.g., has a functional activity). In one embodiment, as many germline residues are introduced into an isolated antibody as possible.
  • mutagenesis is used to substitute or insert one or more germline residues into a CDR region.
  • the germline CDR residue can be from a germline sequence that is similar (e.g., most similar) to the variable region being modified.
  • activity e.g., binding or other functional activity
  • Similar mutagenesis can be performed in the framework regions.
  • a germline sequence can be selected if it meets a predetermined criteria for selectivity or similarity, e.g., at least a certain percentage identity, e.g., at least 75, 80, 85, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99, or 99.5% identity, relative to the donor non-human antibody.
  • the selection can be performed using at least 2, 3, 5, or 10 germline sequences.
  • identifying a similar germline sequence can include selecting one such sequence.
  • identifying a similar germline sequence can include selecting one such sequence, but may include using two germline sequences that separately contribute to the amino-terminal portion and the carboxy- terminal portion. In other implementations, more than one or two germline sequences are used, e.g., to form a consensus sequence.
  • the antibody may be modified to have an altered glycosylation pattern (i.e., altered from the original or native glycosylation pattern).
  • altered means having one or more carbohydrate moieties deleted, and/or having one or more glycosylation sites added to the original antibody. Addition of glycosylation sites to the presently disclosed antibodies may be accomplished by altering the amino acid sequence to contain glycosylation site consensus sequences; such techniques are well known in the art. Another means of increasing the number of carbohydrate moieties on the antibodies is by chemical or enzymatic coupling of glycosides to the amino acid residues of the antibody.
  • an antibody has CDR sequences that differ only insubstantially from those of P2D10. Insubstantial differences include minor amino acid changes, such as substitutions of 1 or 2 out of any of typically 5-7 amino acids in the sequence of a CDR, e.g., a Chothia or Kabat CDR. Typically an amino acid is substituted by a related amino acid having similar charge, hydrophobic, or stereochemical characteristics. Such substitutions would be within the ordinary skills of an artisan. Unlike in CDRs, more substantial changes in structure framework regions (FRs) can be made without adversely affecting the binding properties of an antibody.
  • FRs structure framework regions
  • Changes to FRs include, but are not limited to, humanizing a nonhuman-derived framework or engineering certain framework residues that are important for antigen contact or for stabilizing the binding site, e.g., changing the class or subclass of the constant region, changing specific amino acid residues which might alter an effector function such as Fc receptor binding (Lund et al., J. Immun. 147:2657-62 (1991); Morgan et al., Immunology 86:319-24 (1995)), or changing the species from which the constant region is derived.
  • humanizing a nonhuman-derived framework or engineering certain framework residues that are important for antigen contact or for stabilizing the binding site e.g., changing the class or subclass of the constant region, changing specific amino acid residues which might alter an effector function such as Fc receptor binding (Lund et al., J. Immun. 147:2657-62 (1991); Morgan et al., Immunology 86:319-24 (1995)), or changing the species from which the constant region is
  • the anti-TWEAK or anti-Fn14 antibodies used in the methods of the invention can be in the form of full length antibodies, or in the form of fragments of antibodies, e.g., Fab, F(ab')2, Fd, dAb, and scFv fragments. Additional forms include a protein that includes a single variable domain, e.g., a camel or camelized domain. See, e.g., U.S. 2005-0079574 and Davies et al., Protein Eng. 9(6):531-7 (1996). Antibodies can further be linked to one or more heterologous polypeptides.
  • an anti-Tweak antibody is linked to one or more antigen binding domains of the same or a different antibody.
  • an anti-Tweak antibody can be linked to one or more scFvs, e.g,. at the C- terminus of the Fc portions.
  • the TWEAK antagonist is a soluble Fn14 polypeptide.
  • the sequence of an exemplary human Fn14 is shown in SEQ ID NO:21.
  • the sequence of an exemplary mouse Fn14 is shown in SEQ ID NO:22.
  • An exemplary soluble form of the Fn14 protein includes a region of the Fn14 protein that binds to TWEAK, e.g., about amino acids 32-75, 31-75, 31-78, or 28- 79 of SEQ ID NO:21.
  • the TWEAK antagonist is an Fn 14 fusion protein.
  • the term "fusion protein" refers to a chimeric protein comprising amino acid sequences of two or more different proteins.
  • the Fn14 fusion protein includes, in addition toFn14, one or more polypeptide portions that enhance one or more of in vivo stability, in vivo half-life, uptake/administration, tissue localization or distribution, formation of protein complexes, and/or purification. Fusion proteins may be generated recombinantly using molecular cloning techniques well known in the art.
  • the Fn14 fusion protein contains amino acids 28-79 of SEQ ID NO.21.
  • This region of Fn14 can be physically associated, e.g., fused to another amino acid sequence, e.g., an Fc domain, at its N- or C- terminus.
  • the Fn14 polypeptide can be from the heterologous amino acid sequence spaced by a linker.
  • the Fn14 fusion protein includes a purification subsequence, such as an epitope tag, a FLAG tag, a 6xHis sequence, or GST polypeptide.
  • U.S. Patent No. 6,824,773 describes an exemplary Fn14 fusion protein.
  • the Fn14 fusion protein may contain a mutated form of Fn14 as described above.
  • conservative substitutions of one or more amino acids present in a native Fn 14 polypeptide can be made without adversely effecting the activity of the polypeptide.
  • conservative substitutions include substitution of amino acids outside of regions of Fn 14 that are conserved between species (such as between human and mouse Fn14), and substitution of amino acids that do not alter the secondary and/or tertiary structure of Fn14.
  • substitution of one aliphatic residue for another such as lie, VaI, Leu, or Ala for one another, or substitution of one polar residue for another, such as between Lys and Arg; GIu and Asp; or GIn and Asn, or substitution of one aromatic residue for another, such as Phe, Trp, or Tyr for one another.
  • Other conservative substitutions such as substitutions of entire regions having similar hydrophobicity characteristics, are known in the art and are contemplated in the methods of the invention.
  • Methods of generating mutated forms of Fn14 are well known in the art of molecular biology, and include altering DNA molecules by random mutagenesis, site directed mutagenesis, deletions, and truncations.
  • PCR polymerase chain reaction
  • saturation i.e. chemical or radiation
  • mutagenesis saturation (i.e. chemical or radiation) mutagenesis
  • chemical DNA synthesis alanine scanning mutagenesis
  • oligonucleotide-mediated mutagenesis hybridization to a DNA template in vitro followed by enzymatic elongation
  • cassette recombinant
  • combinatorial mutagenesis introduction of random degenerate sequences into the TWEAK DNA.
  • the methods of the invention employ an Fn14 fusion protein that includes the Fc domain of an immunoglobulin such as, e.g., IgGI , lgG2, lgG3, lgG4), IgE, IgD, IgM (Fn14-Fc).
  • an immunoglobulin such as, e.g., IgGI , lgG2, lgG3, lgG4), IgE, IgD, IgM (Fn14-Fc).
  • the Fc portion of an immunoglobulin has the meaning commonly given to the term in the field of immunology. Specifically, this term refers to an antibody fragment which does not contain the two antigen binding regions (the Fab fragments) from the antibody.
  • the Fc portion consists of the constant region of an antibody from both heavy chains, which associate through non-covalent interactions and disulfide bonds.
  • the Fc portion can include the hinge regions and extend through the CH2 and CH3 domains to the C-terminus of the antibody.
  • the Fc portion can further include one or more glycosylation sites.
  • the immunoglobulin Fc portion of the fusion protein contains mutations designed to remove unwanted effector functions and/or reduce the risk of inducing an immune response after repeated and prolonged administration, as described in U.S. Patent No. 7,452,966.
  • Fn14 has been characterized in J. Biol. Chem., 274: 33166-76 (1999) and International Publication Number WO 02/022166, the entire disclosure of which is incorporated herein by reference.
  • the human and mouse amino acid sequences for this type I transmembrane protein are provided herein as SEQ ID NO:21 and SEQ ID NO:22, respectively.
  • Antibodies and other proteins described herein can be produced in prokaryotic and eukaryotic cells.
  • the antibodies are expressed in a yeast cell such as Pichia (see, for example, Powers et al., J. Immunol. Methods, 251 : 123-35 (2001)), Hanseula, or Saccharomyces.
  • Antibodies particularly full length antibodies, for example, IgG's, and soluble Fn14 proteins may be expressed in mammalian cells.
  • exemplary mammalian host cells for recombinant expression include Chinese Hamster Ovary (CHO cells) (including dhfr CHO cells, described in Urlaub and Chasin, Proc. Natl. Acad. Sci. U. SA, 77: 4216-4220 (1980), in which recombinant constructs include a DHFR selectable marker, as described in Kaufman and Sharp, MoI.
  • lymphocytic cell lines including NSO myeloma cells and SP2 cells, COS cells, K562 cells, and cells from a transgenic animal, such as a transgenic mammal.
  • Antibodies may be expressed in mammary epithelial cells.
  • the recombinant expression vectors may carry additional nucleic acid sequences, such as sequences that regulate replication of the vector in host cells (e.g., origins of replication) and selectable marker genes.
  • the selectable marker gene facilitates selection of host cells into which the vector has been introduced (see e.g., U.S. Pat. Nos. 4,399,216; 4,634,665; and 5,179,017).
  • Exemplary selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr host cells with methotrexate selection/amplification) and the neo gene (for G418 selection).
  • DHFR dihydrofolate reductase
  • a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain is introduced into dhfr CHO cells by calcium phosphate-mediated transfection.
  • the antibody heavy and light chain genes are each operatively linked to enhancer/promoter regulatory elements (e.g., derived from SV40, CMV, adenovirus and the like, such as a CMV enhancer/AdMLP promoter regulatory element or an SV40 enhancer/AdMLP promoter regulatory element) to drive high levels of transcription of the genes.
  • enhancer/promoter regulatory elements e.g., derived from SV40, CMV, adenovirus and the like, such as a CMV enhancer/AdMLP promoter regulatory element or an SV40 enhancer/AdMLP promoter regulatory element
  • the recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification.
  • the selected transformant host cells are cultured to allow for expression of the antibody heavy and light chains and intact antibody is recovered from the culture medium.
  • Standard molecular biology techniques are used to prepare the recombinant expression vector, to transfect the host cells, to select for transformants, to culture the host cells, and to recover the antibody from the culture medium. For example, some antibodies can be isolated by affinity chromatography with a Protein A or Protein G.
  • Antibodies may also include modifications, including, for example, modifications that alter Fc function. Such modifications include changes that decrease or remove interaction with an Fc receptor or with C1q, or both.
  • the human IgGI constant region can be mutated at one or more residues, including, for example, one or more of residues 234 and 237, according to the numbering in U.S. Pat. No. 5,648,260.
  • Other exemplary modifications include those described in U.S. Pat. No. 5,648,260.
  • the protein/antibody production system may be designed to synthesize the fusion protein or antibody proteins in which the Fc region is glycosylated.
  • the Fc domain of IgG molecules is glycosylated at asparagine 297 in the CH2 domain.
  • the Fc domain can also include other eukaryotic post-translational modifications.
  • the protein is produced in a form that is not glycosylated.
  • Antibodies and other proteins can also be produced by a transgenic animal.
  • U.S. Pat. No. 5,849,992 describes a method for expressing an antibody in the mammary gland of a transgenic mammal.
  • a transgene is constructed that includes a milk-specific promoter and nucleic acid sequences encoding the antibody of interest, e.g., an antibody described herein, and a signal sequence for secretion.
  • the milk produced by females of such transgenic mammals includes, secreted-therein, the protein of interest, e.g., an antibody or Fc fusion protein.
  • the protein can be purified from the milk, or for some applications, used directly.
  • the methods of this invention include the administration of an effective dose of a TWEAK antagonist to a subject to prevent or reduce cell death induced by radiation therapy. Determination of a preferred pharmaceutical formulation and a therapeutically efficient dose regiment for a given subject is well within the skill of the art taking into consideration, for example, the condition and weight of the patient, the extent of desired treatment and the tolerance of the patient for the treatment. In some embodiments, the TWEAK antagonist is administered locally to the region of tissue to be treated with radiation therapy. [0131]
  • the TWEAK antagonist can be administered by any route of administration which is compatible with the antagonist, and may be formulated with any pharmaceutically acceptable carrier appropriate to the route of administration. Such carriers are well known to those skilled in the art.
  • Administration can be performed, for example, intravenously, intraperitoneally, orally, via implant, transmucosally, transdermally, intramuscularly, and subcutaneously.
  • Preferred routes of administration are parenteral and, in particular, intravenous, intraperitoneal, and intracapsular.
  • Administration can be performed over an extended period on an outpatient basis, similar in this regard to radiation treatment.
  • Daily dosages of a TWEAK antagonist are expected to be in the range of about 0.01 to 1000 ⁇ g/kg body weight, and more preferably about 10 to 300 ⁇ g/kg body weight, although precise dosages will vary depending upon the agent employed and the particular subject's medical condition and history.
  • the TWEAK antagonist is administered via an injectable drug delivery system.
  • injectable drug delivery system can include solutions, suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering agents (including, for example, ethanol, propylene glycol and sucrose) and polymers (including, for example, polycaprylactones and polylactic-co-glycolic acids (PLGA's)).
  • solubility-altering agents including, for example, ethanol, propylene glycol and sucrose
  • polymers including, for example, polycaprylactones and polylactic-co-glycolic acids (PLGA's)
  • the TWEAK antagonist is delivered to via ultrasound-mediated microbubble destruction. Drugs can be i n corporated into microbubbles in a number of different ways, including binding of the drug to the microbubble shell and attachment of site-specific ligands.
  • microbubble delivery is known in the art, and has been demonstrated to be effective in targeted delivery of biologies (i.e. proteins having a molecular weight of between 5-300 kDa; see, for example, Mukherjee, D., et al. J. Am. Coll. Cardiol. 35:1678-1686 (2000)).
  • biologies i.e. proteins having a molecular weight of between 5-300 kDa; see, for example, Mukherjee, D., et al. J. Am. Coll. Cardiol. 35:1678-1686 (2000)).
  • Oral delivery systems for the TWEAK antagonist include tablets and capsules. These can contain excipients such as binders (e.g., hydroxypropyl- methylcellulose, polyvinyl pyrilodone, other cellulosic materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulosic materials), disintegrating agents (e.g., starch polymers and cellulosic materials) and lubricating agents (e.g., stearates and talc).
  • excipients such as binders (e.g., hydroxypropyl- methylcellulose, polyvinyl pyrilodone, other cellulosic materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulosic materials), disintegrating agents (e.g., starch polymers and cellulosic materials
  • Transmucosal delivery systems for the TWEAK antagonist include patches, tablets, suppositories, pessaries, gels and creams, and can contain excipients such as solubilizers and enhancers (e.g., propylene glycol, bile salts and amino acids), and other vehicles (e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid).
  • solubilizers and enhancers e.g., propylene glycol, bile salts and amino acids
  • other vehicles e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid.
  • Dermal delivery systems include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, liposomes, ointments, aqueous and nonaqueous solutions, lotions, aerosols, hydrocarbon bases and powders, and can contain excipients such as solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrolidone).
  • solubilizers e.g., permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrolidone).
  • permeation enhancers e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids
  • hydrophilic polymers e.
  • the TWEAK antagonist is administered via an implantable system.
  • Implantable systems can include rods and discs, and can contain excipients such as PLGA and polycaprylactone.
  • Solutions, suspensions and powders for reconstitutable delivery systems include vehicles such as suspending agents (e.g., gums, zanthans, cellulosics and sugars), humectants (e.g., sorbitol), solubilizers (e.g., ethanol, water, PEG and propylene glycol), surfactants (e.g., sodium lauryl sulfate, Spans, Tweens, and cetyl pyridine), preservatives and antioxidants (e.g., parabens, vitamins E and C, and ascorbic acid), anti-caking agents, coating agents, and chelating agents (e.g., EDTA).
  • suspending agents e.g., gums, zanthans, cellulosics and sugars
  • humectants e.g., sorbitol
  • solubilizers e.g., ethanol, water, PEG and propylene glycol
  • TWEAK antagonist may, for example, be placed into sterile, isotonic formulations with or without cofactors which stimulate uptake or stability.
  • the formulation is preferably liquid, or may be lyophilized powder.
  • the TWEAK antagonist may be diluted with a formulation comprising 5.0 mg/ml citric acid monohydrate, 2.7 mg/ml trisodium citrate, 41 mg/ml mannitol, 1 mg/ml glycine and 1 mg/ml polysorbate 20.
  • This solution can be lyophilized, stored under refrigeration and reconstituted prior to administration with sterile Water-For- Injection (U.S.P).
  • the TWEAK antagonists of this invention may also be administered using microspheres, liposomes, other microparticulate delivery systems or sustained release formulations placed in, near, or otherwise in communication with affected tissues or the bloodstream.
  • sustained release carriers include semipermeably polymer matrices in the form of shaped articles such as suppositories or microcapsules.
  • Implantable or microcapsular sustained release matrices include polylactides (U.S. Pat. No.
  • the methods, formulations, and dosages of the invention may be evaluated in a known model of irradiation-induced tissue injury. These models include animal models such as the mouse model described in the following examples. When testing the compositions of the invention in animal models, the biological therapeutic agent should have activity in the animal. For example, a mouse anti-TWEAK antibody may be used in lieu of a human antibody if the human antibody does not cross-react with mouse TWEAK.
  • Example 1 The TWEAK/Fn14 pathway has a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis
  • Fn14 expression in the gastrointestinal tract are limited, with moderate mRNA levels observed in normal human tissue mRNA arrays (Wiley et al., Cytokine Growth Factor Rev 14:241-9 (2003)).
  • expression of Fn 14 is well documented in cells of epithelial origin such as bronchial, mammary and bile duct epithelium and human keratinocytes (Jakubowski et al., J CHn Invest 115:2330-40 (2005); Jin et al., J Invest Dermatol 122:1175-9 (2004); Michaelson et al., Oncogene 24:2613-24 (2005); Xu et al., Biochem Biophys Res Commun 318:422-7 (2004)).
  • TWEAK is proinflammatory (Burkly et al., Cytokine 40:1-16 (2007)); or (3) TWEAK represses innate immunity (Maecker et al., Cell 123:931- 44 (2005)).
  • TNBS-induced colitis is a model of human IBD in which intrarectal instillation of TNBS with ethanol injures the epithelial barrier followed by a T cell me ⁇ iated immune response against haptenated colonic proteins, leading to mucosal inflammation and epithelial damage involving both innate and adaptive immune components.
  • the ⁇ - irradiation injury model (Example 2) induces much more limited damage directed at the rapidly dividing progenitor cells of the intestinal crypts without a significant inflammatory component (Booth et al., lnt J Cancer 86:53-9 (2000); Leedham et al., J Cell MoI Med 9:11-24 (2005)).
  • TWEAK/Fn14 pathway a novel pathogenic mediator in models of intestinal injury, promoting pathology through its effects on epithelial cell inflammatory responses and turnover. TWEAK deficiency limits local intestinal pathology without impairing systemic adaptive immune responses.
  • TWEAK or Fn14 knockout mice were backcrossed onto Balb/c or C57BL/6 backgrounds for 5-6 generations under SPF conditions at Biogenrez or the International Medical Center of Japan (IMCJ). All experimental protocols were approved by the institutional animal care and use committees. Generation of the TWEAK- and Fn14-deficient mice
  • TWEAK KO mice were generated as described (Campbell et al., J Immunol 176:1889-98 (2006)).
  • a 8.12-kb Hind ⁇ subclone containing 3.36 kb of upstream sequence and the first five exons of the TWEAK gene was obtained from a BAC clone of 129 sv/J genomic DNA (Genome Systems).
  • the targeting vector was constructed from this subclone using the bacterial recombination method (Zhang, Y., et al. Nat. Genet. 20: 123-128 (1998)).
  • TWEAK-deficient mice were generated by standard procedures using homologous recombination in embryonic stem cells (Bronson, S. K., et al. Proc. Natl. Acad. Sci. USA 93: 9067-9072 (1996)).
  • the neomycin expression cassette was excised from the locus by mating TWEAK heterozygous mice with MSX2-Cre recombinase-expressing mice (Lewandoski, M., et al. Nat.
  • mice Homozygous TWEAK-deficient, neomycin-deleted mice were generated by breeding heterozygous mice. Absence of TWEAK mRNA expression in knockout mice was confirmed by RT-PCR and Northern blot using the full length TWEAK cDNA, and GAPDH probed as a control. TWEAK knockout (KO) mice were backcrossed onto Balb/c backgrounds for 5-6 generations under specific pathogen free (SPF) conditions. Expression of genes neighboring the TWEAK locus was unaltered.
  • SPF pathogen free
  • Fn14 KO mice generation of Fn14 KO mice was described (Jakubowski et al., J CHn Invest 115:2330-40 (2005)).
  • a 10-kb Kpn1 genomic DNA fragment containing the full murine Fn14 gene was isolated, and a targeting vector was designed to delete the first 2 exons, which contained the entire extracellular ligand-binding domain of Fn14.
  • the target vector was transfected into the J1 129 ES cell line and selected with G418.
  • ES cell clones were screened for homologous recombination using Southern blot, and the correct clones were injected into C57BL/6 blastocysts to generate chimeras.
  • mice heterozygous for targeted Fn14 alleles were obtained through further breeding and identified using Southern blot or PCR.
  • the null mutation was confirmed by both Northern blot and RT-PCR. Mice were bred to homozygosity on the 129 background.
  • the Fn14 mutation was backcrossed 5 times onto the C57BL/6 background under SPF conditions.
  • TNBS colitis was induced by intrarectal administration of a 2 % solution of TNBS in PBS:ethanol (1 :1) as described in Dohi et al., Gastroenterology 119:724-33 (2000) and Dohi et al., J Exp Med 189:1169-80 (1999).
  • 60 ⁇ g/g body weight of TNBS was given on day 0 and animals sacrificed on day 3.
  • 36 ⁇ g/g body weight of TNBS was administered on days 0 and 7 with sacrifice on day 10.
  • mice were treated with murine anti-TWEAK mAb P2D10 (Campbell et al., J Immunol 176:1889-98 (2006)) or isotype-matched control Pl 17 (ATCC, Manassas, VA), 300 ⁇ g on days 3 and 7 with sacrifice on day 10, or as otherwise specified.
  • the colons of surviving mice were cut into proximal, middle and distal segments, formalin-fixed, paraffin-embedded and 4- ⁇ m sections stained with H&E. Each colon segment was scored individually and these scores were summed to reach a total score for the entire colon. Histological scores were assigned to each segment as follows: 0 - normal, 1 - ulcer or cell infiltration limited to the mucosa, 2 - ulcer or limited cell infiltration in the submucosa, 3 - focal ulcer involving all layers of the colon, 4 - multiple lesions involving all layer of the colon or necrotizing ulcer larger than 3mm in length. Thus the total possible histological score is 12.
  • the SV40 immortalized, nontransformed cell lines MODE-K (Vidal et al., J Immunol Methods 166:63-73 (1993)) and MCE301 (Tabuchi et al., Cell Struct Fund 25:297-307 (2000)) were cultured with media alone, or with specified concentrations of murine TWEAK, soluble Fn 14 plus TWEAK, an agonistic anti- Fn14 mAb P2.D3 or isotype-matched control Ig, MOPC-21 , for 24 hours.
  • Culture supernatants were analyzed by SearchLight multiplex ELISA (Pierce Boston Technology Center, Woburn, MA) for chemokines, cytokines and MMPs. Cell subsets analysis for WT and TWEAK KO mice
  • TWEAK KO and WT splenocytes were stained using antibodies (BD Biosciences) for: CD3, CD4, CD8, IgM, NK1.1 , DX5, CD44 and CD62L. lmmunohistochemistry for fluorescently-stained samples
  • Fn14 detection was carried out as described above with double staining for PE-labeled EpCAM mAb or PE-labeled anti-F4/80 (Becton, Dickinson and Company, 1 :200 dilution) for 2 hours at room temperature.
  • PE-labeled EpCAM mAb or PE-labeled anti-F4/80 Becton, Dickinson and Company, 1 :200 dilution
  • 1 mg bromodeoxyuridine (BrdU) was injected i.p.
  • jejunum was collected at 24 hours post irradiation, and paraffin- embedded sections were deparaffinized, treated with 4N HCI, blocked with 1% BSA and stained with rat anti-BrdU antibody (Oxford Biotech, Ltd, United Kingdom) followed by FITC-labeled anti-rat IgG (Southern Biotechnology Associates, Inc., Birmingham, AL). Numbers of BrdU + cells were counted in 20 separate crypts in 3 or more fields for each animal.
  • Fn14 expression was evaluated as relative expression to the mean value for cultures with media alone.
  • Fn14 mRNA increased in TNBS-treated colons of Balb/c mice
  • a gene profiling study was conducted with Balb/c colons collected 3 days after intrarectal TNBS/EtOH to determine acute changes in gene expression.
  • animals were given a second dose of TNBS on day seven and colons collected three days later (day 10) to examine the later phase of the pathology.
  • Three members of the TNFR superfamily showed significant up- regulation in colons of TNBS-treated mice in comparison to untreated controls in both the acute and late stages of colitis (Figure 1).
  • TNFR1 and 2 were increased, however expression of their ligand TNF ⁇ was not detected, consistent with the prior report of no effect of TNF blockade in TNBS-induced colitis in the Balb/c strain ⁇ Dohi et al., J Immunol 167:2781-90 (2001)).
  • TWEAK KO mice have normal immune system/intestinal architecture
  • TWEAK deficient animals were healthy and normal.
  • Comprehensive necropsy revealed no abnormalities, and extensive immune compartment analysis showed normal spleen weights in both young and aged mice, and normal percentages and absolute numbers of splenic B, T, NK, and NKT cell subsets and activated/memory cells within the CD4 and CD8 T cell populations ( Figures 5, 6, 7, 8).
  • Baseline levels of Ig subclasses were also comparable to those of WT mice (data not shown).
  • TWEAK KO mice protected from TNBS-induced colitis/ulceration
  • TWEAK KO mice exhibited a significantly lower histological score than WT controls (Figure 13) reflecting two prominent differences on both days 3 and 10: reduction in frequency and extent of epithelial ulcers and reduction in leukocyte infiltration into the submucosa. The overall magnitude of inflammatory cell infiltration was also reduced in TWEAK KO as compared on WT colons at both the early and late disease stages ( Figure 14).
  • TNBS colitis was also induced in TWEAK or Fn14 deficient mice on the C57BL/6 background. A similar protective effect was seen in this strain in the absence of either TWEAK or Fn14 ( Figure 15). Additionally, WT Balb/c mice were treated with an anti-TWEAK blocking antibody starting either on day 0 ( Figures 16, 17) or starting 3 days after TNBS administration and diminished clinical score and histological damage to the colon likewise observed ( Figures 18, 19). Taken together, these results indicate that TWEAK/Fn14 pathway contributes to both the onset and progression of TNBSinduced colitis.
  • TWEAK KO mice exhibited a significantly reduced level of peroxidase activity (Figure 20 A&B), and staining for neutrophil marker Gr-1 ( Figure 20 C&D) was likewise diminished. Monocyte infiltration was also reduced in TWEAK KO colons ( Figure 20 E&F).
  • TNBS colitis is also associated with a robust adaptive immune response to trinitrophenyl (TNP)-modified proteins.
  • TWEAK deficiency did not alter generation of the TNP-specific T cell response in draining sacral lymph nodes ( Figure 21 left graph) or serum levels of anti-TNP antibodies ( Figure 21 , right graph). These findings suggest that TWEAK deficiency ameliorates local pathogenic events rather than the systemic adaptive immune component.
  • chemokines/chemokine receptors were markedly reduced in TWEAK KO colons. Most of the chemokines affected were those involved in neutrophil and monocyte chemotaxis. Some of these chemokines are known to be secreted by colon epithelial cells (CXCL1 , CXCL5, CCL2), while others are produced by activated macrophages (CXCL2, CCL3) and serve to recruit additional cells into the tissue (Papadakis Curr Allergy Asthma Rep 4:83-9 (2004)).
  • MMPs matrix metalloproteinases
  • TWEAK induces epithelial cell production of inflammatory mediators
  • TWEAK TWEAK and its receptor, Fn 14, were identified.
  • TWEAK was expressed by intestinal epithelial cells in WT tissue ( Figure 23), whereas expression by other cell types was equivocal, warranting further investigation. TWEAK expression was similar before and 3 days after disease induction. In contrast, there was little if any Fn14 in normal WT colon ( Figure 24, upper left panel) whereas Fn 14 expression by colon epithelial cells was markedly increased in WT mice three days after TNBS administration ( Figure 24, middle left panel).
  • TWEAK stimulation of proinflammatory mediator production was also observed with the MCE301 cell line ( Figures 30, 31). These results suggest that TWEAK acts locally through Fn 14 expressing epithelial cells to promote pathogenic tissue inflammation and matrix remodeling in TNBS colitis. Anti-TWEAK antibody protects WT Balb/c mice from colitis
  • FIG. 32 shows the TNBS-induced colitis histology scores of WT mice, TWEAK KO mice, WT mice treated with control Ig, and WT mice treated with anti-TWEAK monoclonal antibody three and ten days after administration of TNBS. Antibodies were injected on day 0, day 3, and day 7 of TNBS-induced colitis.
  • TWEAK/Fn14 pathway As a nonredundant pathogenic mediator in contexts of intestinal injury and inflammatory disease.
  • Significant amelioration of TNBS-induced colitis is observed in TWEAK or Fn14 deficient mice, and in WT mice treated with TWEAK blocking mAbs prophylactically or therapeutically.
  • TWEAK deficient animals show an improved clinical course, reduced colon epithelial ulcers and less infiltration by granulocytes and macrophages.
  • TWEAK does not regulate the systemic adaptive response to TNP.
  • blocking TWEAK can be an intervention point for inhibiting local immune effector mechanisms, as well as controlling epithelial injury, in contexts of intestinal injury and inflammatory disease. Blocking TWEAK can be a favorable intervention point, since it orchestrates events specific to the disease target tissue without systemically impairing host immunity. .
  • the TWEAK KO mice of the present study were extensively characterized, with no differences observed between KO and WT. Since full length TWEAK cDNA was used as a probe in the Northern blot analysis, it is extremely unlikely that TWEAK is expressed in the test animals.
  • Intestinal epithelial cells markedly upregulate Fn14 after TNBS administration. Although other local Fn14 expressing cells cannot be ruled out, colon infiltrating macrophages do not appear to express this receptor. Intestinal epithelium is a well established player in the innate defense of the intestine (Abreu et al., J Immunol 174:4453-60 (2005)). The present in vitro studies suggest that Fn14 can be induced by exposure to bacterial DNA after injury to the epithelial barrier. Although TNF ⁇ is not expressed in the Balb/c strain after TNBS administration, it might may also induce Fn14 in contexts of intestinal injury on other genetic backgrounds.
  • Intestinal epithelial cells also respond to TWEAK, with increased production of chemokines involved in monocyte and neutrophil recruitment and MMP-9. Conversely, expression of these gene signatures was significantly reduced locally in TWEAK KO as compared to WT colons. While the pathogenic role of inflammatory cytokines, chemokines and MMPs in models of colitis is well established (Papadakis Curr Allergy Asthma Rep 4:83-9 (2004); Naito et al., MoI Aspects Med 26:379-90 (2005)), the present studies identify TWEAK as an important instigator of their production in TNBS induced colitis apparently through stimulation of intestinal epithelial cells.
  • TWEAK was previously shown to significantly contribute to joint inflammation and damage in mouse collagen-induced arthritis, likely through its effect on mesenchymal joint cell types, without affecting systemic collagen-specific T cell antibody responses (Kamata et al., J Immunol 177:6433-6439 (2006); Perper et al., J Immunol 177:2610-20 (2006)). These studies underscore the important disease-promoting contribution of TWEAK-epithelial and TWEAK-stromal cell interactions locally in the disease target tissue.
  • MMPs enzymes important for degradation of extracellular matrix proteins and cell migration are significantly increased after TNBS administration in WT mice and may contribute to disease pathogenesis in multiple ways.
  • MMP-9 was shown to be abundantly associated with inflamed areas in ulcer bases in human IBD tissue (Arihiro et al., Histopathology 39:50-9 (2001)) and MMP-3 shown to produce severe tissue injury in gut explant cultures (Pender et al., J Immunol 160:4098-103 (1998)).
  • proteolysis by MMPs may contribute to ulcer formation and severity
  • reduced MMPs including MMP-3 and MMP-9 in TWEAK KO animals may contribute to reduced ulceration.
  • MMPs are also involved in accumulation of inflammatory cells into the intestine in TNBS colitis as evidenced by reduced neutrophil accumulation in MMP inhibitor treated animals (Di Sebastiano et al., Digestion 63:234-9 (2001); Sykes et al., Aliment Pharmacol Ther 13:1535-42 (1999)).
  • reduced MMP expression in TWEAK KO mice may contribute to decreased inflammation.
  • TWEAK has been demonstrated to induce MMP-9 dependent proliferation and branching of mammary gland epithelial cells in vitro (Michaelson et al., Oncogene 24:2613-24 (2005)). Decreased anchorage of epithelial cells as a consequence of matrix degradation may trigger cell proliferation and branching.
  • TWEAK-induced MMP activity may reduce epithelial anchoring and thereby promote cell proliferation, crypt deformity and branching, features of abnormal repair observed 10 days after TNBS insult. These features are reduced in the TWEAK KO mice.
  • TWEAK produced by adaptive and innate cell types acts on epithelial cells to enhance the local production of well known inflammatory mediators, tissue remodeling enzymes, and regulate epithelial turnover.
  • Anti-TNF- ⁇ antibody treatment was a milestone in the therapy of Crohn's disease (Targan et al., N Engl J Med 337:1029-35 (1997)) and now in ulcerative colitis (Rutgeerts et al., N Engl J Med 353:2462-76 (2005). However, 30-40% of patients are refractory to this treatment. Thus new therapeutics are sought to address this unmet need.
  • Example 2 TWEAK or Fn14 deficiency reduces intestinal epithelial cell death following ⁇ -irradiation
  • TWEAK- or Fn14-KO mice received 3 Gy of whole-body irradiation using the ⁇ -irradiation apparatus MBR-1520-R (Hitachi Medical Corporation, Tokyo, JAPAN). Twenty-four hours post-irradiation, the mice were sacrificed, and small intestine and colon were collected. Paraffin-embedded sections were prepared from a Swiss roll of whole colon or a 7 cm length from the oral end of the small intestine for analysis of jejunum. Numbers of apoptotic cells per crypt, detected in H&E stained sections by chromatin condensation, were counted in 20 separate crypts in 3 or more fields for each animal.
  • Balb/c TWEAK-KO mice showed a significantly lower number of apoptotic cells than WT in both jejunum and colon after 3 Gy of whole-body irradiation.
  • Representative H&E stained images of crypts from Balb/c WT and TWEAK-KO jejunum and colon samples 24 hours after irradiation are shown in Figure 33. Apoptotic cells in a single representative crypt are indicated by arrowheads.
  • the number of apoptotic cells in the jejunum or colon crypts in Balb/c WT or TWEAK-KO mice is shown in Figure 34. Asterisks indicate p ⁇ 0.01.
  • Example 3 TWEAK deficiency increases the appearance of regenerating epithelial cells after irradiation
  • mice [0185] The effect of TWEAK deficiency on cell survival was also assessed by measuring cell regeneration in intestinal epithelial cells of WT and TWEAK- deficient mice receiving radiation treatment.
  • Balb/c WT and Balb/c TWEAK-KO mice received 12 Gy of whole-body irradiation using the ⁇ -irradiation apparatus MBR-1520-R (Hitachi Medical Corporation, Tokyo, JAPAN).
  • MBR-1520-R Haitachi Medical Corporation, Tokyo, JAPAN.
  • mice were sacrificed, and small intestine was collected. Paraffin- embedded sections of both the jejunum and ileum were prepared for H&E staining and analysis.
  • Example 4 Enhanced survival of intestinal epithelial cells in
  • TWEAK deficiency was also assessed by measuring cell proliferation in intestinal epithelial cells of WT and TWEAK- deficient mice receiving radiation treatment.
  • the number of proliferating cells in crypts of Balb/c WT and TWEAK-KO mice and in C57BL/6 WT and Fn 14-KO mice after irradiation was determined.
  • 1 mg 5-bromo-2'-deoxy-uridine (BrdU; Sigma-Aldrich) was injected intraperitoneally into the mice 1 hour prior to sacrifice.
  • Jejunum was collected at 24 hours post irradiation, and paraffin-embedded sections were deparaffinized, treated with 4N HCl, blocked with 1% BSA and stained with rat anti-BrdU antibody (Oxford Biotech, Ltd, United Kingdom) followed by FITC-labeled anti-rat IgG (Southern Biotechnology Associates, Inc., Birmingham, AL). Numbers of BrdU + cells were counted in 20 separate crypts in 3 or more fields for each animal.
  • TWEAK participates in TNF ⁇ -induced apoptosis pathway

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des méthodes de prévention des lésions tissulaires induites par la radiothérapie. L'invention concerne, selon certains aspects et pour partie, la découverte selon laquelle la perturbation de la signalisation d'un membre de la famille du TNF, TWEAK (faible inducteur de l'apoptose ressemblant au TNF), par l'intermédiaire de son récepteur Fn 14 réduit les niveaux de mort cellulaire chez les cellules épithéliales et favorise la régénération des cellules épithéliales suite à une radiothérapie chez un modèle murin de lésion tissulaire par irradiation γ. Des modes de réalisation de l'invention impliquent l'utilisation d'un antagoniste du TWEAK à des fins de prévention ou de réduction de la mort cellulaire survenant suite à une radiothérapie.
PCT/US2010/021809 2009-01-23 2010-01-22 Procédé de réduction des lésions tissulaires induites par une irradiation WO2010085648A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14704909P 2009-01-23 2009-01-23
US61/147,049 2009-01-23

Publications (2)

Publication Number Publication Date
WO2010085648A2 true WO2010085648A2 (fr) 2010-07-29
WO2010085648A3 WO2010085648A3 (fr) 2010-09-16

Family

ID=42356400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/021809 WO2010085648A2 (fr) 2009-01-23 2010-01-22 Procédé de réduction des lésions tissulaires induites par une irradiation

Country Status (1)

Country Link
WO (1) WO2010085648A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440189B2 (en) 1999-01-15 2013-05-14 Biogen Idec Ma Inc. Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
US8506958B2 (en) 2002-04-09 2013-08-13 Biogen Idec Ma Inc. Methods for treating TWEAK-related conditions
US8728475B2 (en) 2005-05-10 2014-05-20 Biogen Idec Ma Inc. Methods for treating inflammatory bowel disease
US9730947B2 (en) 2005-06-13 2017-08-15 Biogen Ma Inc. Method of treating lupus nephritis
US9775899B2 (en) 2005-02-17 2017-10-03 Biogen Ma Inc. Treating neurological disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020041876A1 (en) * 1999-12-20 2002-04-11 Wiley Steven R. TWEAK receptor
US20030039613A1 (en) * 1993-11-30 2003-02-27 Unger Evan C. Novel therapeutic delivery systems
US20080279853A1 (en) * 2005-05-27 2008-11-13 Biogen Idec Ma Inc. Treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030039613A1 (en) * 1993-11-30 2003-02-27 Unger Evan C. Novel therapeutic delivery systems
US20020041876A1 (en) * 1999-12-20 2002-04-11 Wiley Steven R. TWEAK receptor
US20080279853A1 (en) * 2005-05-27 2008-11-13 Biogen Idec Ma Inc. Treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DOHI ET AL.: 'TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis' GASTROENTEROLOGY vol. 136, no. 3, March 2009, pages 912 - 913 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440189B2 (en) 1999-01-15 2013-05-14 Biogen Idec Ma Inc. Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
US8506958B2 (en) 2002-04-09 2013-08-13 Biogen Idec Ma Inc. Methods for treating TWEAK-related conditions
US9011859B2 (en) 2002-04-09 2015-04-21 Biogen Idec Ma Inc. Methods for treating TWEAK-related conditions
US9775899B2 (en) 2005-02-17 2017-10-03 Biogen Ma Inc. Treating neurological disorders
US8728475B2 (en) 2005-05-10 2014-05-20 Biogen Idec Ma Inc. Methods for treating inflammatory bowel disease
US9730947B2 (en) 2005-06-13 2017-08-15 Biogen Ma Inc. Method of treating lupus nephritis

Also Published As

Publication number Publication date
WO2010085648A3 (fr) 2010-09-16

Similar Documents

Publication Publication Date Title
ES2938625T3 (es) Anticuerpo monoclonal humano para CD134 (OX40) humana y procedimientos de preparación y utilización del mismo
US9387237B2 (en) Methods of treating a patient having an autoimmune disorder by administering a soluble BCMA
EP0663836B1 (fr) Traitement d'affections auto-immunes et inflammatoires
US8173126B2 (en) Blood VEGF level-lowering agent containing IL-6 antagonist as the active ingredient
KR101125127B1 (ko) 자가면역 및 염증성 질병과 기관 이식 거부반응의 치료를위해 사용되는 길항제 항-ｃｄ４０ 항체의 사용 방법
JP6181043B2 (ja) 抗神経成長因子抗体ならびにそれを調製および使用する方法
TWI552760B (zh) 拮抗劑抗－ｉｌ－７受體抗體及方法
KR101352416B1 (ko) 신규의 완전한 사람형 항-ｖａｐ-1 모노클로날 항체
Jennette et al. Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies
EP2077120A2 (fr) Remède contre l'arthrite rhumatoïde contenant un antagoniste il-6 en tant qu'ingrédient actif
US8454956B2 (en) Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
EA011479B1 (ru) Антитело связывающееся с ngf, и способы его применения
EA027499B1 (ru) Антитела к cd37
DK2340039T3 (en) Use of IL-20 antagonists for treating osteoporosis
WO2010085648A2 (fr) Procédé de réduction des lésions tissulaires induites par une irradiation
JP2023025212A (ja) 放射線障害の治療又は予防剤並びに治療又は予防方法
KR20220151195A (ko) 항-cd36 항체 및 암을 치료하기 위한 이의 용도
EP3896086A1 (fr) Anticorps anti-il-17a et son utilisation
AU2013203707B2 (en) Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis
AU2009302383B9 (en) Use of IL-20 antagonists for treating rheumatoid arthritis and osteoporosis
CN114980901A (zh) 使用针对浆细胞的抑制剂或细胞毒性剂治疗慢性疲劳综合征的方法
NZ617448B2 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
EP0765171A1 (fr) Traitement des troubles auto-immuns et inflammatoires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10733904

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10733904

Country of ref document: EP

Kind code of ref document: A2